FEDERAL COURT OF AUSTRALIA
Generic Health Pty Ltd v Otsuka Pharmaceutical Co., Ltd [2013] FCAFC 17
Citation: Generic Health Pty Ltd v Otsuka Pharmaceutical Co., Ltd [2013] FCAFC 17 Appeal from: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2012] FCA 239 Parties: GENERIC HEALTH PTY LTD (ACN 110 617 859) v OTSUKA PHARMACEUTICAL CO., LTD and BRISTOL-MYERS SQUIBB COMPANY File number: NSD 490 of 2012 Judges: EMMETT, BENNETT AND GREENWOOD JJ Date of judgment: 6 March 2013 Addendum: 8 March 2013 Catchwords: PATENTS – s 117(2)(b) of the Patents Act 1990 (Cth) – whether supplier of product, which was not a staple commercial product, had reason to believe that the person to whom product supplied would put the product to an infringing use
PATENTS – appeal against interlocutory injunction – threatened supply of generic pharmaceutical products – whether prima facie case of infringement – whether prima facie case in a Beecham sense – whether assessment or evaluation of strength of prima facie case required – whether balance of convenience and justice favours the grant of interlocutory injunctive relief
Legislation: Patents Act 1990 (Cth) ss 117(1), 117(2)(a), 117(2)(b), 117(2)(c)
Patents Act 1977 (UK) ss 60(2), 60(3)
Patent Act 1952 (US)Cases cited: Apple Inc v Samsung Electronics Co Limited [2011] HCA Trans 341
Australian Broadcasting Corporation v O’Neill (2006) 227 CLR 57
Aktiebolaget Hassle v Alphapharm Pty Limited (2002) 212 CLR 411
Apotex Pty Ltd v Sanofi-Aventis Australia Pty Limited (No 2) (2012) 204 FCR 494
Australian Coal and Shale Employees’ Federation v The Commonwealth (1953) 94 CLR 621
BeechamGroup Ltd v Bristol Laboratories Pty Ltd (1968) 118 CLR 618
Collins v Northern Territory (2007) 161 FCR 549
Grimme Landmaschinenfabrik GmbH & Co KG v Scott [2010] EWCA Civ 1110; (2010) 89 IPR 631
Jackson v Sterling (1987) 162 CLR 612
Jonker v Platform Solutions Pty Limited [2012] FCA 237
KCI Licensing v Smith & Nephew Plc [2010] EWCA Civ 1260; [2010] All ER (D) 203 (Nov).
KCI Licensing v Smith & Nephew Plc [2010] EWHC 1487 (Pat); [2010] FSR 740
Northern Territory v Collins (2008) 235 CLR 619
Samsung Electronics Co Limited v Apple Inc (2011) 286 ALR 257
Sigma Pharmaceuticals (Australia) Pty Limited v Wyeth (2009) 81 IPR 339Date of hearing: 30 July 2012 Place: Sydney Division: GENERAL DIVISION Category: Catchwords Number of paragraphs: 263 Counsel for the applicant: AH Bowne SC with ADB Fox Solicitor for the applicant: Middletons Counsel for the respondents: AJ Bannon SC with C Cochrane Solicitor for the respondents: Allens
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 490 of 2012
ON APPEAL FROM THE FEDERAL COURT OF AUSTRALIA
BETWEEN: GENERIC HEALTH PTY LTD (ACN 110 617 859)
ApplicantAND: OTSUKA PHARMACEUTICAL CO., LTD
First RespondentBRISTOL-MYERS SQUIBB COMPANY
Second Respondent
JUDGE:
GREENWOOD J
DATE:
8 MARCH 2013
PLACE:
BRISBANE
ADDENDUM TO REASONS FOR JUDGMENT OF JUSTICE GREENWOOD
In my reasons for judgment published on 6 March 2013, together with the reasons for judgment…
Keep reading for free
Create a free CaseChat account to read Generic Health Pty Ltd v Otsuka Pharmaceutical Co., Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2013] FCAFC 17
- Decision Date
CaseChat Overview and Summary
The court considered the nature of the products supplied and the requisite knowledge for an infringement under section 117(2)(b) of the Act. It noted that the products were not staple commercial products and that the issue of whether they were such products was not necessary to decide. The court found that there was a prima facie case that Generic Health had reason to believe that the products would be put to an infringing use, based on the evidence of the use of aripiprazole to treat cognitive impairment associated with schizophrenia. The court also held that an assessment of the strength of the prima facie case was not required under Beecham Group Ltd v Bristol Laboratories Pty Ltd and that the balance of convenience and justice favoured the grant of interlocutory injunctive relief. The court concluded that the appeal against the interlocutory injunction should be refused, and the applicant should pay the respondent’s costs.
Orders
Orders of the court
1. Leave to appeal be refused.
2. The applicant pay the respondent’s costs of the application for leave.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
His Honour considered the question of “staple commercial product” and said (at [93]) that the approach contended for by Otsuka was ‘open on the present evidence’. His Honour said that it was not necessary to express a final view on whether the GH Products were, or were not, staple commercial products and declined to do so, but said that it was sufficient to be satisfied that there was a prima facie case that the GH Products were not staple commercial products. ConsiderationSubmissions on prima facie case Generic Health submits that the primary judge gave no basis for his conclusion that there was, objectively, a reason to believe on its part that the GH Products would be put to an infringing use. Generic Health says that that there was no evidence of knowledge on its part of the use to which the GH Products would be put. None of the evidence cited by the primary judge related to actual knowledge on the part of Generic Health of the matters arising from the evidence of Professor Singh and Professor McGorry. Generic Health says that the case presented by Otsuka rises no higher than there being a prospect that clinicians may switch a patient in the manner disclosed in claim 7. It also points out that there is no evidence that the GH Products will be used in a method of treatment that has all of the integers of claim 7. That is, it submits, there are also no objective criteria by which a finding that it had reason to believe that its products would be used in the method of claim 7 can be supported. There was no product information or other direction from Generic Health instructing that the GH Products be used for the infringing use. Generic Health relies upon the finding of the primary judge at [103] that there was no evidence that would enable him to conclude, with any reasonable level of confidence, that prescribing doctors would read into the Generic Health product information an instruction that the GH Products are to be used or can be used in the method of treatment specifically claimed in claim 7. The product information did not give that instruction expressly or impliedly. Accordingly, s 117(2)(c) did not apply. Generic Health relies on this finding as antithetical to a conclusion that s 117(2)(b) applies, saying that the evidence did not rise above there being a prospect of a ‘switch’ being made. This is not a case where the supplier has provided instructions or directions for an infringing use (cf Apotex v Sanofi-Aventis). For the purposes of this appeal, it is not contended that the product supplied is a staple commercial product (cf Collins (HC)). The question is whether the supply of aripiprazole to treating doctors, who then prescribe it, is an infringement of s 117(2)(b). There is no present suggestion that Generic Health had actual knowledge that the product would be put to an infringing use. The primary judge explained the use to which at least some doctors would put the product, to treat not only schizophrenia but also the cognitive impairment with which the forms of schizophrenia are associated. This arises, at least, from the use of aripiprazole as a second generation treatment of schizophrenia.